Ashling Wahner

Articles

BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

January 23rd 2024

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

Oral HMAs May Provide Safer and More Effective Treatment Options for MDS

January 23rd 2024

Guillermo Garcia-Manero, MD, spotlights the evolution of oral azacitidine- and decitabine-based regimens for MDS.

Neoadjuvant Botensilimab/Balstilimab Combo Induces Early Efficacy in pMMR/dMMR CRC

January 20th 2024

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

177Lu-Dotatate Prolongs PFS Vs High-Dose Octreotide in GEP-NETs

January 20th 2024

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

Investigational Targeted Therapies Broaden Glioma Research Efforts and Define Disease Subsets

January 15th 2024

Ashley Sumrall, MD, FACP, discusses ongoing research with the DRD2 dopamine receptor–targeted agent ONC201 in patients with H3K27M-mutated glioma.

Acalabrutinib Is Not Associated With Increased Hypertension Risk in CLL

January 11th 2024

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension linked with BTK inhibitors in chronic lymphocytic leukemia.

NALIRIFOX Prolongs Survival With a Tolerable Safety Profile in mPDAC

January 11th 2024

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL

January 9th 2024

BRL-201 had a manageable safety profile and elicited early indications of efficacy in patients with relapsed/refractory non-Hodgkin lymphoma.

Sequencing BCMA-Directed Therapies Expands Multiple Myeloma Treatment Horizons

January 8th 2024

Sikander Ailawadhi, MD, spotlights the characteristics of multiple myeloma that drive the decision to use teclistamab-cqyv, elranatamab-bcmm, or talquetamab-tgvs.

Asciminib Provides MMR Benefits vs SOC TKIs in Newly Diagnosed Ph+ CML

January 8th 2024

Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Iopofosine I 131 Generates Efficacy Signals in Waldenström Macroglobulinemia

January 8th 2024

Iopofosine I 131 monotherapy elicited durable responses and was associated with a tolerable safety profile in patients with heavily pretreated, multi-class refractory Waldenström macroglobulinemia.

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

January 5th 2024

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC

January 4th 2024

Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.

POSEIDON Update Confirms OS Benefit of Tremelimumab/Durvalumab Plus Chemo in mNSCLC

January 3rd 2024

A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.

FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC

January 2nd 2024

The FDA has issued a complete response letter to the supplemental new drug application seeking the full approval of sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer.

Revisit the Top 5 OncLive On Air Episodes of 2023

December 29th 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

The Intersections of Career Direction and Personal Connections

December 27th 2023

With perseverance, compassion, and energy, Ann H. Partridge, MD, MPH, has devoted her career to shrinking the gaps in research and care for young women with breast cancer and improving their outcomes and quality of life along the way.

Combination Regimens Expand RCC and Prostate Cancer Treatment Armamentariums

December 26th 2023

Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal agents plus androgen deprivation therapy in frontline metastatic hormone-sensitive prostate cancer.

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

December 22nd 2023

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment

December 21st 2023

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.